CorMedix Inc.

CorMedix Inc. announced its third-quarter 2026 financial results, reporting consolidated revenue of $54.5 million, surpassing analyst expectations. The company also revealed a net loss of $14.7 million and an Adjusted EBITDA of $3.1 million. A significant development is the definitive asset purchase agreement to acquire substantially all assets of Heron Therapeutics, Inc., which is expected to be immediately accretive. CorMedix also provided an update on its REZZAYO sNDA for an expanded indication and secured a $150 million term loan facility. Full-year 2026 guidance was maintained for revenue and narrowed for Adjusted EBITDA.

CorMedix Inc. announced a definitive asset purchase agreement to acquire substantially all of the assets of Heron Therapeutics for an upfront consideration of $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal, valued at approximately $222.6 million based on CorMedix's recent stock price, includes potential additional earn-out payments of up to $55 million tied to ZYNRELEF sales. This acquisition will expand CorMedix's portfolio with four commercial-stage products, including ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, and is expected to be immediately accretive to earnings and free cash flow, generating significant operating cost synergies. CorMedix has secured $75 million in non-dilutive financing from Pharmakon Advisors to support the transaction, which is anticipated to close in the first quarter of 2027.

CorMedix Inc. reported strong financial results for the second quarter and first half of 2026, significantly boosted by the acquisition of Melinta Therapeutics in August 2025. For the three months ended June 30, 2026, total revenue and grant income reached $101.9 million, leading to a net income of $26.0 million. For the six months ended June 30, 2026, total revenue and grant income was $229.4 million, with net income at $64.6 million. The company also noted a $10.9 million expense from the change in fair value of contingent consideration for the first half of 2026.

CorMedix Inc. reported strong second-quarter 2026 financial results, with consolidated revenue of $101.9 million and net income of $26.0 million. Adjusted EBITDA reached $58.7 million, and basic EPS was $0.33. The company also announced a new multi-year commercial supply agreement for DefenCath, expanding its footprint to all top 5 U.S. dialysis providers. CorMedix maintained its full-year 2026 revenue guidance while raising its adjusted EBITDA guidance to $125 million to $140 million.

CorMedix Inc. announced strong financial results for the second quarter of 2026, with consolidated revenue reaching $101.9 million and net income of $26.0 million. Adjusted EBITDA significantly increased to $58.7 million. The company maintained its full-year 2026 revenue guidance while raising its adjusted EBITDA guidance to a range of $125 million to $140 million. Additionally, CorMedix secured a new multi-year commercial supply agreement for DefenCath and anticipates submitting an sNDA for REZZAYO's expanded indication in Q3 2026.

CorMedix Inc. announced that the U.S. District Court for the District of New Jersey granted preliminary approval for the proposed settlement of a consolidated derivative lawsuit and a related shareholder derivative action. The settlement resolves allegations that individual defendants breached fiduciary duties, leading to delayed FDA approval of DefenCath. It includes the implementation and maintenance of corporate governance reforms for at least three and a half years. A final settlement hearing is scheduled for September 23, 2026, and plaintiffs' counsel intends to seek up to $3.9 million in attorneys' fees.

CorMedix Inc. announced it will release its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. Following the release, the company will host a corporate update conference call at 8:30 AM Eastern Time on the same day to discuss the results.

CorMedix Inc. announced a change in its executive leadership structure. Elizabeth Hurlburt, previously Chief Operating Officer, has been appointed to the newly created role of Chief Operating and Commercial Officer. In this expanded role, she will oversee all commercial functions, medical affairs, regulatory, and clinical, continuing to report to Chairman & CEO Joseph Todisco. Concurrently, Michael Seckler has departed from the company.

CorMedix Inc. announced a change in its independent registered public accounting firm. On June 25, 2026, the company dismissed CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) for the fiscal year ending December 31, 2026. There were no disagreements with CBIZ CPAs on accounting principles, financial disclosure, or auditing scope, except for a previously disclosed material weakness in internal control over financial reporting related to non-routine transactions.

CorMedix Inc. has secured a significant legal victory as the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's judgment. The ruling confirms that Nexus Pharmaceuticals Inc.'s generic minocycline product infringes two of CorMedix's patents and rejects Nexus's challenge to the patents' validity. This decision upholds a permanent injunction against Nexus, preventing them from marketing their generic product until patent expiration, and validates the intellectual property protecting CorMedix's MINOCIN® for Injection.